Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group

Faiss, Siegbert; Pape, Ulrich‐Frank; Böhmig, Michael; Dörffel, Yvonne; Mansmann, Ulrich; Golder, W.; Riecken, E. O.; Wiedenmann, Bertram

doi:10.1200/jco.2003.12.142

Cited by 461 publications

(278 citation statements)

References 29 publications

Supporting

Mentioning

248

Contrasting

Unclassified

Order By: Relevance

“…Significantly better 5-year survival rates have been reported from single centers after active interventions (Wängberg et al 1996, Sarmiento & Que 2003. The only curative treatment is radical surgery, but for palliation of symptoms the treatment can include cytoreductive surgery, ischaemic treatment of liver metastases or medical therapy with somatostatin analogues sometimes combined with interferon a (Kvols et al 1986, Faiss et al 2003, Kölby et al 2003, Roche et al 2003, Osborne et al 2006. Recently, somatostatin receptormediated radiotherapy has been introduced as palliative treatment (Kwekkeboom et al 2005(Kwekkeboom et al , 2008.…”

Section: Introductionmentioning

confidence: 99%

High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids

Andersson¹,

Swärd²,

Stenman³

et al. 2009

Endocrine-Related Cancer

View full text Add to dashboard Cite

Ileal carcinoids are malignant neuroendocrine tumours of the small intestine. The aim of this study was to obtain a high-resolution genomic profile of ileal carcinoids in order to define genetic changes important for tumour initiation, progression and survival. Forty-three patients with ileal carcinoids were investigated by high-resolution array-based comparative genomic hybridization. The average number of copy number alterations (CNAs) per tumour was 7

show abstract

Section: Introductionmentioning

confidence: 99%

High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids

Andersson¹,

Swärd²,

Stenman³

et al. 2009

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…There is also a risk of hepatotoxicity, autoimmune disorders and the development of neutralizing antibodies. It is useful to note that in a recent prospective randomized trial using interferonalpha alone, somatostatin analogue alone, or the combination showed no additional benefit of the combination over the monotherapies (Faiss et al 2003).…”

Section: Interferon-alpha and Chemotherapy For Gut Neuroendocrine Tummentioning

confidence: 99%

Neuroendocrine tumours.

Barakat¹,

Meeran²,

Bloom³

2004

Endocr Relat Cancer

201

110

View full text Add to dashboard Cite

Neuroendocrine tumours are a heterogeneous group including, for example, carcinoid, gastroenteropancreatic neuroendocrine tumours, pituitary tumours, medullary carcinoma of the thyroid and phaeochromocytomas. They have attracted much attention in recent years, both because they are relatively easy to palliate and because they have indicated the chronic effect of the particular hormone elevated. As neuroendocrine phenotypes became better understood, the definition of neuroendocrine cells changed and is now accepted as referring to cells with neurotransmitter, neuromodulator or neuropeptide hormone production, dense-core secretory granules, and the absence of axons and synapses. Neuroendocrine markers, particularly chromogranin A, are invaluable diagnostically. Study of several neuroendocrine tumours has revealed a genetic etiology, and techniques such as genetic screening have allowed risk stratification and prevention of morbidity in patients carrying the particular mutation. Pharmacological therapy for these often slow-growing tumours, e.g. with somatostatin analogues, has dramatically improved symptom control, and radiolabelled somatostatin analogues offer targeted therapy for metastatic or inoperable disease. In this review, the diagnosis and management of patients with carcinoid, gut neuroendocrine tumours, multiple endocrine neoplasia types 1 and 2, and isolated phaeochromocytoma are evaluated.

show abstract

“…Several subsequent phase II studies of recombinant interferon-alpha-2a, alone or in combination with 5-fluorouracil, reported symptomatic improvement and variable response rates in patients with NETs [49 -51]. Combination studies of interferon-alpha plus a somatostatin analogue as compared to somatostatin analogue monotherapy have shown response rates of 5%-6% with one of three studies favoring an improved overall survival with combination therapy [52][53][54]. In each of these studies, carcinoids and PNETs were evaluated together.…”

Section: Interferonmentioning

confidence: 99%

A New Era for the Systemic Therapy of Neuroendocrine Tumors

Eads

2012

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Describe the underlying biology of neuroendocrine tumors including pancreatic neuroendocrine tumors (PNETs) and carcinoids and the importance of these biologic features in the evolution of new drugs for these diseases.2. Cite the historical data regarding the use of cytotoxic agents in the treatment of pancreatic neuroendocrine tumors and carcinoids.3. Explain the significance of recent clinical trials utilizing biologic agents, in particular octreotide, the small molecule tyrosine kinase inhibitor, sunitinib and the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and how these medications have altered the natural history of both pancreatic neuroendocrine tumors and carcinoids.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTCarcinoids and pancreatic neuroendocrine tumors are becoming increasingly common, with the majority of patients presenting with either lymph node involvement or metastatic disease. An improved understanding of the molecular mechanisms involved in these tumors has implicated several pathways that have led to new therapeutic approaches. In this manuscript, we describe the biology of neuroendocrine tumors and approaches to systemic therapy. We review early data regarding the use of cytotoxics and several recent studies employing more targeted approaches that promise to change the standard of care. Specifically, phase III studies indicate that pharmacologic inhibition of the vascular endothelial growth factor pathway with sunitinib, and of the mammalian target of rapamycin pathway with everolimus, appears to have altered the natural history of these diseases. These successes set the stage for further advances in the management of patients with neuroendocrine tumors. The Oncologist 2012; 17:326 -338Correspondence: Neal J. Meropol, M.D.,

show abstract

Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group

Cited by 461 publications

References 29 publications

High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids

High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids

Neuroendocrine tumours.

A New Era for the Systemic Therapy of Neuroendocrine Tumors

Contact Info

Product

Resources

About